Mary Hobart, PhD

Efficacy of Adjunctive Brexpiprazole in Major Depressive Disorder: A Pooled Response Quartile Analysis

Background: We assessed varying levels of response to brexpiprazole adjunctive to standard antidepressant therapy (ADT).

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Mary Hobart , PhD;

Dalei Chen , PhD;

11/22/2019

Predictors of Weight Change After Long-Term Treatment With Brexpiprazole in Schizophrenia

Background: We assessed effects contributing to weight gain during long-term treatment with brexpiprazole.

Mette Josiassen , PhD;

Anders Tvistholm , MS;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Mary Hobart , PhD;

Ross Baker , PhD, MBA;

11/22/2019

Long-term Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Objective: The Orion study (NCT01360866) evaluated the long-term safety, tolerability, and therapeutic effect of brexpiprazole (0.5–3 mg/day), as adjunct to antidepressant treatment, in a...

Aleksandar Skuban , MD;

Claudette Brewer , BA;

Peter Zhang , PhD;

Nanco Hefting , MSc;

Mary Hobart , PhD;

03/01/2019

Effect of Adjunctive Brexpiprazole on Sexual Functioning in MDD According to Concomitant Antidepressant: Post Hoc Analysis of Four Short-Term Studies

Background: We aimed to determine the effects of adjunctive brexpiprazole on sexual functioning in adults with major depressive disorder (MDD), according to antidepressant treatment (ADT)...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

Malaak Brubaker , PhD;

Peter Zhang , PhD;

Mary Hobart , PhD;

11/22/2019